Samsung Bioepis announces one-year results from Phase 3 study of SB11, a proposed biosimilar to Lucentis (ranibizumab), at the American Academy of Ophthalmology (AAO) 2020 Virtual

Press/Media: Press / Media

Period2020 Nov 13

Media coverage

1

Media coverage

  • TitleSamsung Bioepis announces one-year results from Phase 3 study of SB11, a proposed biosimilar to Lucentis (ranibizumab), at the American Academy of Ophthalmology (AAO) 2020 Virtual
    Media name/outletFirstWord Pharma
    Country/TerritoryUnited States
    Date20/11/13
    URLwww.firstwordpharma.com/node/1774479
    PersonsKyunghwan Kim